13-valent Pneumococcal Conjugate Vaccine (PCV-13)

The clinical application was submitted to China National Institute for Food and Drug Control (CNIFDC) in April, 2018, and the Registration Acceptance Number was received afterwards. It’s estimated that the phase I trial could be finished in 2023.

Varicella-zoster Virus Vaccine (VZV)

The project for VZV uses special antigen design and has completely independent intellectual property. The vaccine doesn’t require complicated adjuvant system because of its unique design, which has high safety. Body immunity could be induced after inoculation, and strong humoral immunity and cell immunity could be induced both because of its good immunogenicity.

Attenuation Rotavirus Vaccine, pentavalent

The virus strain of the project was introduced from overseas, and the vaccine using the same virus strain has been marketed in foreign countries with clear efficacy and safety, which can fill in gaps in the domestic multivalent rotavirus vaccine market.

Respiratory Syncytial Virus Vaccine (RSV)

The RSV vaccine is a kind of viral vector vaccine, the replication-deficient adenovirus type 5(Ad5) is used as viral vector, and the F protein that induces RSV envelope to fuse with the host cell is the primary target of RSV vaccine. It could avoid the problems of virulence reversion for the live attenuated vaccines and disease enhance for the inactivated vaccine.

The project is now in the stage of sample preparation for pilot scale, and the progress of the project is relatively pioneering in China.

Broad-spectrum Human Papillomavirus Vaccine (HPV)

BravoVax signed the cooperation agreements with National Institute of Health (NIH）and Johns Hopkins University (JHU) for the global exclusive rights of development, market and intellectual property license for the next-generation HPV vaccine.

The animal experiments showed that the vaccine has cross-protection for all HPV serotypes, and it is a true "broad-spectrum” and universal HPV candidate vaccine.

COVID-19 vaccine (BravoCoVac®)

Taking the newest Coronavirus immunological research and its vaccine achievements into consideration, a brand new COVID-19 vaccine with disease and infection prevention, high efficiency against mutant strains is hopefully to be provided in the combination of unique technical platform, antigen design and administration routes.

Next-generation Pneumococcal Conjugate Vaccine（NG-PCV）

Utilize the successful experience of clinical trials and industrialization of PCV-13 to quickly move NG-PCV to clinical trials and industrialization, and greatly shorten the development cycle.